Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Pihlajalinna Plc publishes Interim Report for January 1–September 30, 2024, on Thursday, 7 November 2024

Pihlajalinna Plc          Investor News          25 October 2024 at 2:35 p.m. Pihlajalinna Plc publishes Intermin Report for January 1–September 30, 2024, on Thursday, 7 November 2024 Pihlajalinna Plc will publish the Interim Report for the period of January 1–September 30, 2024, on Thursday, 7 November 2024, at approximately 8:00 a.m. The release will be available on the company website  after publication.  Live webcast Pihlajalinna will organise a live webcast meeting for analysts, investors and media

Multiple contract awards in Brazil

Solstad Offshore ASA (Solstad) is pleased to announce multiple contract awards with Clients in Brazil. · AHTS “Normand Topazio” has been awarded a 1-year contract with commencement in October 2024, in direct continuation of current contract. · AHTS “Normand Turmalina” has been awarded a 1-year contract with commencement in November 2024, in direct continuation of current contract. · CSV “Normand Cutter” has been awarded a 9-month contract for subsea construction activities with commencement in October 2024 in direct continuation of current contract. The combined gross

poLight ASA - Invitation to presentation of Q3 2024 results

poLight ASA (OSE: PLT) will release its third quarter 2024 results on Thursday 31 October 2024 at 7.00 am CEST. The quarterly report and presentation will be made available on the company's website www.polight.com and www.newsweb.no. CEO Øyvind Isaksen and CFO Joakim Hines Bredahl will present the company's results at 09:00 am CEST at Continental, Stortingsgaten 24/26, in Oslo, Norway which is open to the public. The presentation and supporting material will be in English. The presentation can also be followed through live webcast. Please join the Q3 2024 results webcast by clicking here:

Invitation: Sobi’s Aspaveli® and the Phase 3 VALIANT data in Nephrology call

VALIANT Phase 3 results after presentation at ASNInvestors, analysts, and members of the media are invited to a conference call on Tuesday, October 29th, at 12:00 CET, 11:00 GMT, and 07:00 EDT. The call will include a presentation of results and insights from management and Professor Fadi Fakhouri following the American Society of Nephrology (ASN) and a Q&A session.   The presentation can be followed live here  or afterwards on sobi.com. The slides will be made available on sobi.com 

Panel talk about Inify’s third quarter 2024

Inify Laboratories have decided to establish its operation to the United Kingdom and expand diagnostics to the gastrointestinal field. One of the major challenges in the UK is long and unpredictable response times and varying quality in prostate cancer care. The market is six times larger than Sweden´s in terms of patient volume, with approximately 120,000 patients annually who require diagnosis. "The national health care system NHS in the UK has a high focus on pathways for patients that are going through cancer investigations, and here is exactly where we provide unique

Interim report January-September 2024

JULY – SEPTEMBER 2024 · Sales amounted to 4,977 MSEK (5,461). · EBIT amounted to 800 MSEK (930). · EBIT-margin amounted to 16.1 percent (17,0). · Profit after tax amounted to 559 MSEK (670). · Earnings per share amounted to 1.62 SEK (1.95). · Operating cash flow amounted to 803 MSEK (963). JANUARY – SEPTEMBER 2024 · Sales amounted to 15,743 MSEK (17,178). · EBIT amounted to 2,616 MSEK (2,821). · EBIT-margin increased to 16.6 percent (16.4). · Profit after tax amounted to 1,867 MSEK (2,017). · Earnings per share amounted to 5.42 SEK (5.86). ·

Interim Report January—September 2024: Margin protection and growth focus in a challenging market

The third quarter · Order intake decreased to 456 MSEK (514). · Net sales decreased to 493 MSEK (619). · EBIT amounted to 50.8 MSEK (89.2). · EBIT margin was 10.3% (14.4). · Profit after tax amounted to 31.1 MSEK (52.5). · Earnings per share reached 1.08 SEK (1.81). · Free cash flow tripled to 55.6 MSEK (17.5). · Cost control and strengthened gross margin resulted in maintained EBIT margin compared to the second quarter of 2024.    Nine months · Order intake decreased to 1,467 MSEK (1,829). · Net sales amounted to 1,680 MSEK (1,881). · EBIT was 185.

INTERIM REPORT JANUARY − SEPTEMBER 2024

JANUARY − SEPTEMBER 2024 · Rental revenue increased 16% to SEK 3,678 M (SEK 3,160 M in the year-earlier period). · Profit from property management attributable to the Parent Company’s shareholders increased 8% to SEK 3,217 M (2,972). · Profit from property management per Class A and B share after dilution amounted to SEK 8.94 (8.64). · Property revaluation had an impact on profit of SEK 456 M (–1,680). · Revaluation of financial instruments had an impact on profit of SEK 1,074 M (–734), of which SEK 1,335 M referred to the revaluation of Sagax’s holding in NP3 Fastigheter

Invitation to third quarter results 2024 and Capital Markets Day

Multiconsult (OSE: MULTI) will release third quarter 2024 results and Capital Markets Day presentation on Wednesday 6 November at 07:00 CET. A presentation of the results, followed by Capital Markets Day, will be held at Hotel Continental and broadcast as a live webcast.Multiconsult hereby invites you to the presentations, and all participants are invited to attend. Presentations to be held in English at Hotel Continental, Stortingsgata, 24/26, Oslo. Programme:08:15                                Doors open08:30                                Third quarter result 202409:15 - 10:30

Invitation to presentation in connection with EQL Pharma's interim report, second quarter, 2024/25

EQL Pharma AB (publ) will publish its interim report for the second quarter, 2024/25, on Wednesday, November 6[th], before stock markets opening.At 10.00 (CET) 6[th] November, the company will give a presentation via video conference. The presentation is aimed at shareholders and potential shareholders. CEO and President Axel Schörling presents and comments on the interim report. After the presentation, there is an opportunity to ask questions for those who participate. Use the following link to access the virtual meeting: https://tinyurl.com/jszm8ecf Date and time November 6[th],

Aquaporin signs new contract with the European Space Agency

Aquaporin Space Alliance (ASA), a joint venture between Aquaporin and Danish Aerospace Company (DAC), has signed a new contract with ESA (European Space Agency) for the development of a Water Recovery System (WRU) for use in space.The new contract is part of ESA’s General Support Technology Program and covers the development of a full-ground prototype of a future space water purification system. The Danish Aerospace Company and Aquaporin have worked on various technological aspects for such a system for several years, including flying three company-funded water cleaning technology

Dispelix and RTX’s Collins Aerospace to collaborate on aerospace and defense technology

Dispelix, a global leader in augmented reality (AR) waveguide display technology, and Collins Aerospace, an RTX business, have announced a long-term supply agreement to incorporate Dispelix’s advanced AR waveguide displays into Collins Aerospace’s products.Under the agreement, Dispelix will leverage its expertise in designing and developing state-of-the-art waveguide displays to supply Collins Aerospace with advanced near-eye and head-up displays. By working together, Dispelix and Collins will be able to offer next-generation solutions, leveraging waveguide technology, to a broader range of

APM Terminals Maasvlakte II B.V. chooses Automated Horizontal Transport System from Konecranes to support doubling of its Rotterdam terminal capacity

· Order includes 71 battery-powered Konecranes Lift Automated Guided Vehicles (Lift AGVs), TEAMS ECS extension to operate 100+ AGVs, a Third Battery Exchange Station and CONTROLS Emulation software · Konecranes also to provide services for integration, commissioning and automation · Order booked in Q3 2024, with delivery and commissioning expected to begin in 2025 APM Terminals Maasvlakte II B.V. has chosen an extensive Automated Horizontal Transport System from Konecranes as part of a project to double its capacity at the Port of Rotterdam, Europe’s largest port. The order from

Metso opens DRI Smelting Furnace pilot facility in Pori, Finland

Metso Corporation’s press release on October 25, 2024, at 1 p.m. EESTMetso has opened a state-of-the-art DRI (direct reduced iron) Smelting Furnace pilot facility in Pori, Finland. The new facility, opened on October 25, 2024, will allow customer-specific pilot-scale testing to demonstrate the applicability and results of industrial-scale DRI smelting with Metso’s Outotec[®] DRI Smelting Furnace technology. “This new pilot facility is yet another example of Metso’s cutting-edge solutions that support the minerals and metals processing industry in the quest to implement new sustainable

Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds

Oslo, 25 October 2024: Reference is made to the stock exchange announcement by Circio Holding ASA (OSE:CRNA) (“CIRCIO” or the “Company“) on 23 October 2024, regarding the requested conversion of convertible bonds by Atlas Special Opportunities, LLC. The share capital increase has now been registered with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret). The Company’s new share capital is NOK 15,211,804.20 divided into 25,353,007 shares, each with a nominal value of NOK 0.60.

CapMan Real Estate to build Scandinavia's biggest integrated solar roof at Stationsparken, Copenhagen

CapMan Real Estate Release25 October 2024 at 12:30 pm EEST CapMan Real Estate to build Scandinavia's biggest integrated solar roof at Stationsparken, Copenhagen CapMan Real Estate embarks on an ambitious roof renovation at Stationsparken in Glostrup, Copenhagen, involving installing a 7,500 square meter integrated solar roof, which will be the largest of its kind in Scandinavia. The project will generate enough renewable electricity to power a large part of the property and is an example of the type of investments CapMan Real Estate makes to drive transitions to renewable energy

Data from the phase 3 SIERRA trial of Iomab-B presented at the annual European Association of Nuclear Medicine (EANM) Congress 2024

Stockholm, October 25, 2024 – Immedica is pleased to announce that data from the Phase 3 SIERRA trial of Iomab-B was presented in both an oral and a poster presentation at the 2024 European Association of Nuclear Medicine (EANM) Congress, held in Hamburg from October 19-23. Immedica is collaborating with Actinium Pharmaceuticals on the development of Iomab-B. Dr. Neeta Pandit-Taskar, Molecular Imaging and Therapy, Memorial Sloan Kettering Cancer Center, New York, U.S. presented the results: Details of the EANM oral presentation: Title (OP-097): “Modeling-based Assessment of

Form 8.3 - Centamin Plc

FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION   +--------------------------------------------------+---------------------------+|(a) Full name of discloser: |Ninety One UK Ltd |+--------------------------------------------------+---------------------------+|(b) Owner or controller of interests and short |  ||positions disclosed, if different from

Form 8.3 - Anglogold Ashanti Plc

FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION   +--------------------------------------------------------+---------------------+|(a) Full name of discloser: |Ninety One UK Ltd |+--------------------------------------------------------+---------------------+|(b) Owner or controller of interests and short positions|  ||disclosed, if different from 1(a):

Annual Financial Report - Availability

FIDELITY ASIAN VALUES PLC   LEI: 54930094CXNYINSNOQ96   ANNUAL FINANCIAL REPORT Following the release of the Full Year Results Announcement by Fidelity Asian Values PLC (the "Company") for the year ended 31 July 2024 on 11 October 2024, the Company announces that it has published the 2024 Annual Report and Accounts. The document is available to view on the Company's website and a copy has been submitted to the National Storage Mechanism and will be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism Printed copies of the Annual

Veidekke: Change of leadership in Veidekke’s Swedish construction business

After five years heading Veidekke’s Swedish construction business, Charlotta Nilsén is now leaving the position. Martin Gadd (48) who has worked in various parts of the Veidekke Group since 2012 will assume the position. He comes from a role as responsible for “Special Units” within Veidekke’s Norwegian Infrastructure business. Martin takes up his new role today and will at the same time become a member of Veidekke’s corporate management. “I would like to thank Charlotta for her efforts over the years in Veidekke – and particularly for her hard work to improve the construction business

RaySearch appoints new CFO

RaySearch Laboratories AB (publ) announces that Nina Grönberg has been appointed new CFO of the company, taking up her position 27 January 2025.Nina has extensive experience from leadership positions in the finance field in several international and publicly listed companies. She most recently held the role of CFO in the healthcare company Team Olivia, and prior to that, CFO at Duroc, as well as leading roles in accounting, reporting, and business control at Ratos and Munters. Nina Grönberg says: “RaySearch is an innovative company and a driving force in the fight against cancer. The

There are no items matching the current filter
There are no more items matching the current filter
Back to top